Genetic testing can help determine a person's risk for developing certain cancers. Identifying cancer genes, the presence of BRCA 1 and 2 mutations, is the first step. This testing allows the implementation of risk-reducing interventions: more frequent screening, surgical prevention and chemoprevention.
For patients and families at risk for hereditary breast and ovarian cancer due to BRCA mutations, the information gained from genetic testing not only provides answers, but raises questions, too. On Saturday, Sept. 21, Beaumont Health System is hosting a day-long conference for patients and families seeking information and support.
While there are no fees to attend the symposium, registration is required.To register, call 800-633-7377 or go online at classes.beaumont.edu and search for BRCA. Lunch will be provided.
Explains Dana Zakalik, M.D., corporate director, Cancer Genetics Program, Beaumont Health System, "This is the only symposium of its kind in Michigan that combines education and support for those with BRCA genetic mutations. We're connecting, reaching out, to the BRCA community statewide."
The symposium will take place from 8 a.m. to 3 p.m. at Beaumont Hospital, Royal Oak in classrooms A1 and A2 on the main level of the Administration Building, 3711 W. 13 Mile Road.
The conference will address many topics, including:
-cancer genetics overview
-updates in cancer risk management
Lisa Schlager, vice president of Community Affairs and Public Policy, Facing Our Risk of Cancer Empowered, also known as FORCE, will be the keynote speaker.
Beaumont Health System's Cancer Genetics Program provides patients with the most up-to-date information about hereditary cancer risks and guidelines for cancer screenings and treatments. The multidisciplinary team includes certified genetic counselors, oncologists and research coordinators.
About Beaumont's Cancer Program
Beaumont's comprehensive cancer program combines the expertise of surgical, medical and radiation oncologists to offer cancer prevention counseling, diagnosis and treatment in hospital and community-based settings. The Beaumont Cancer Institute is one of only 49 Community Clinical Oncology Programs in the country designated by the National Cancer Institute to provide patients with access to leading-edge cancer clinical research trials. Beaumont is designated as a Blue Cross Center of Distinction for the Treatment of Rare and Complex Cancers. Beaumont, Royal Oak and Troy are recognized by U.S. News and World Report as "high performing" hospitals for cancer care. Find out more at http://cancer.beaumont.edu/.
# # #